Temocillin (6 g daily) in critically ill patients: Continuous infusion versus three times daily administration

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 3, 2015, Pages 891-898

  Laterre, Pierre François ^a   Wittebole, Xavier ^a   Van De Velde, Sebastien ^b,f   Muller, Anouk E ^c   Mouton, Johan W ^d   Carryn, Stéphane ^b,g   Tulkens, Paul M ^b   Dugernier, Thierry ^a,e  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^c MEDICAL CENTER HAAGLANDEN   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e Clinique Saint Pierre of Ottignies   (Belgium)

^f Eumedica SA   (Belgium)

^g GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Continuous veno venous haemofiltration; ESBLs; Free concentration; Monte Carlo simulations; Target attainment rate; Tolerance

Indexed keywords

TEMOCILLIN; ANTIINFECTIVE AGENT; PENICILLIN DERIVATIVE;

ABDOMINAL INFECTION; AGED; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL SUPERINFECTION; BACTERIUM ISOLATION; BLOOD CULTURE; BLOODSTREAM INFECTION; CLINICAL ARTICLE; CONTINUOUS HEMOFILTRATION; CONTINUOUS INFUSION; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DRUG BLOOD LEVEL; DRUG EFFICACY; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ENTEROBACTERIACEAE INFECTION; ESCHERICHIA COLI; FEMALE; GRAM POSITIVE BACTERIUM; HUMAN; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; LOWER RESPIRATORY TRACT INFECTION; MALE; MAXIMUM PLASMA CONCENTRATION; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MORGANELLA MORGANII; PROTEUS MIRABILIS; RANDOMIZED CONTROLLED TRIAL; SERRATIA MARCESCENS; TREATMENT DURATION; URINARY TRACT INFECTION; ADULT; COMPARATIVE STUDY; CRITICAL ILLNESS; ENTEROBACTERIACEAE INFECTIONS; INTRAABDOMINAL INFECTIONS; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PROSPECTIVE STUDY; RESPIRATORY TRACT INFECTIONS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CRITICAL ILLNESS; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HUMANS; INTRAABDOMINAL INFECTIONS; MALE; MIDDLE AGED; ORGANIZATION AND ADMINISTRATION; PENICILLINS; PROSPECTIVE STUDIES; RESPIRATORY TRACT INFECTIONS;

EID: 84928188953     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku465     Document Type: Article

References (26)

1. Livermore DM, Tulkens PM. Temocillin revived. J Antimicrob Chemother 2009; 63: 243-5.
2. Matagne A, Lamotte-Brasseur J, Dive G et al. Interactions between active-site-serine b-lactamases and compounds bearing a methoxy side chain on the a-face of the b-lactam ring: kinetic and molecular modelling studies. Biochem J 1993; 293: 607-11.
3. Rodriguez-Villalobos H, Bogaerts P, Berhin C et al. Trends in production of extended-spectrum b-lactamases among Enterobacteriaceae of clinical interest: results of a nationwide survey in Belgian hospitals. J Antimicrob Chemother 2011; 66: 37-47.
4. Livermore DM, Hope R, Fagan EJ et al. Activity of temocillin against prevalent ESBL- and AmpC-producing Enterobacteriaceae from southeast England. J Antimicrob Chemother 2006; 57: 1012-4.
5. Adams-Haduch JM, Potoski BA, Sidjabat HE et al. Activity of temocillin against KPC-producing Klebsiella pneumoniae and Escherichia coli. Antimicrob Agents Chemother 2009; 53: 2700-1.
6. Tarnberg M, Ostholm-Balkhed A, Monstein HJ et al. In vitro activity of b-lactam antibiotics against CTX-M-producing Escherichia coli. Eur J Clin Microbiol Infect Dis 2011; 30: 981-7.
7. Titelman E, Iversen A, Kahlmeter G et al. Antimicrobial susceptibility to parenteral and oral agents in a largely polyclonal collection of CTX-M-14 and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae. APMIS 2011; 119: 853-63.
8. Kim B, Kim J, Seo MR et al. Clinical characteristics of communityacquired acute pyelonephritis caused by ESBL-producing pathogens in South Korea. Infection 2013; 41: 603-12.
9. Balakrishnan I, Awad-El-Kariem FM, Aali A et al. Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC b-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 2011; 66: 2628-31.
10. De Jongh R, Hens R, Basma V et al. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008; 61: 382-8.
11. Taccone FS, Laterre PF, Dugernier T et al. Insufficient b-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care 2010; 14: R126.
12. Roberts JA, Kruger P, Paterson DL et al. Antibiotic resistance-what's dosing got to do with it? Crit Care Med 2008; 36: 2433-40.
13. Craig WA, Ebert SC. Continuous infusion of b-lactam antibiotics. Antimicrob Agents Chemother 1992; 36: 2577-83.
14. Mouton JW, Vinks AA. Continuous infusion of b-lactams. Curr Opin Crit Care 2007; 13: 598-606.
15. Shull VH, Dick JD. Determination of ticarcillin levels in serum by highpressure liquid chromatography. Antimicrob Agents Chemother 1985; 28:597-600.
16. Mouton JW, Dudley MN, Cars O et al. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother 2005; 55: 601-7.
17. Baririan N, Chanteux H, Viaene E et al. Stability and compatibility study of cefepime in comparison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. J Antimicrob Chemother 2003; 51: 651-8.
18. Servais H, Tulkens PM. Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients. Antimicrob Agents Chemother 2001; 45: 2643-7.
19. Vincent JL, Moreno R, Takala J et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 1996; 22: 707-10.
20. Roberts JA, Webb S, Paterson D et al. A systematic review on clinical benefits of continuous administration of b-lactam antibiotics. Crit Care Med 2009; 37: 2071-8.
21. Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 2010; 49: 71-87.
22. Hsaiky L, Murray KP, Kokoska L et al. Standard versus prolonged doripenem infusion for treatment of gram-negative infections. Ann Pharmacother 2013; 47: 999-1006.
23. Wolff F, Deprez G, Seyler L et al. Rapid quantification of six b-lactams to optimize dosage regimens in severely septic patients. Talanta 2013; 103:153-60.
24. Bo SN, Li HL, Zhu X et al. [Pharmacokinetics ofmeropenemadministered with prolonged infusion time in patients receiving continuous veno-venous hemofiltration]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2012; 24: 145-8.
25. Knaus WA, Draper EA, Wagner DP et al. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-29.
26. Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of b-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 2003; 17: 479-501.